Tirzepatide vs Liraglutide
The dual GIP/GLP-1 agonist vs a single-receptor GLP-1 — the newest metabolic research against the established daily option. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.
Tirzepatide
ApprovedAlso: Mounjaro, Zepbound
Tirzepatide is a man-made copy of two natural gut hormones. It works on two body signals at once, which is why it gets a lot of attention.
Liraglutide
ApprovedAlso: PF-07976016 and Liraglutide, Liraglutide and Exercise
Liraglutide is a medicine that acts like a natural hormone in the body. It is used by doctors to help people with type 2 diabetes control their blood sugar levels.
At a Glance
| Tirzepatide | Liraglutide | |
|---|---|---|
| Research status | Approved | Approved |
| Highest-tier evidence | Peer-reviewed study | Peer-reviewed study |
| Research citations | 64 | 21 |
| Dosing routes | SubQ | SubQ |
| Receptor targets | GIP receptor, GLP-1 receptor | — |
| Half-life | 5 days | — |
| Known side effects | 130 | 97 |
Research Areas
Top preclinical research areas — cited studies for each.
Tirzepatide
- Weight loss (~20.9%)
- Glycemic control
- Superior to semaglutide 1 mg
Liraglutide
- Glycemic Control in Type 2 Diabetes
- Reduction in Waist Circumference
- Reduction in Visceral Adipose Tissue (VAT)
- Improvement of glycemic control in T2D via pancreatic GLP-1R activation
- Significant weight loss and reduced energy intake via brain GLP-1R action
How People Use It
Reported routines — research only, not medical advice.
Tirzepatide
- SubQ — Up to 15 mg
- SubQ — Once weekly subcutaneous injection
- SubQ — Once weekly injection under the skin
- SubQ — Injected once weekly
- SubQ — 36-week trial duration
- SubQ — Once weekly injection
- SubQ — Once-weekly subcutaneous dosing
- SubQ — 10 mg or 15 mg
Liraglutide
- SubQ — Once daily administration
- SubQ — Daily
- SubQ — Once-daily, dose adjusted individually
- SubQ — 3 mg once daily
- SubQ — 0.6 mg daily (Week 1), 1.2 mg daily (Standard), 1.8 mg daily (Max)
- SubQ — 3 mg daily
- SubQ — 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg
- SubQ — 0.6 mg, 1.2 mg, or 1.8 mg
- SubQ — Single subcutaneous injection
- SubQ — Single subcutaneous injection
- SubQ — Once daily
The Evidence
Key studies — click through to verify each on PubMed.
Tirzepatide
64 sourced studies
- Source
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
MetaAnalysis2022 88/100Rated 88/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea
2025 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Liraglutide
21 sourced studies
- Source
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
2020 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
2009 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Liraglutide and Renal Outcomes in Type 2 Diabetes.
2017 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
Decision Guide
How to Choose
Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.
Source Tirzepatide
Shop TirzepatideSource Liraglutide